A disturbed relationship between chaperone proteins and the protein α-synuclein was linked to cell damage and the development of Lewy bodies, which are common in those diagnosed with Parkinson disease, according to study findings.
A disturbed relationship between chaperone proteins and the protein α-synuclein was linked to cell damage and the development of Lewy bodies, which are common in those diagnosed with Parkinson disease (PD), according to study findings published today in the journal Nature.
Currently, there are no distinguishable causes of PD, but it has become well accepted that the protein α-synuclein plays a chief role in the development of PD. When α-synuclein shows negative tendencies, it causes critical cell damage that can lead to the formation of Lewy bodies. In healthy cells, α-synuclein is always accompanied by chaperone proteins, which serve as molecular bodyguards that maintain the protein as transportable and available. However, when these assisting proteins fail to protect α-synuclein in human cells, risk of Lewy body formation heightens, subsequently raising the risk of PD.
Researchers sought to analyze the relationship between chaperone proteins and α-synuclein to distinguish where interaction occurs and its contribution to Lewy body development. In human cells, 30 to 40 of the molecular bodyguards can potentially interact with α-synuclein.
Utilizing novel NMR technology, the scientists found segments of α-synuclein that interact with the individual chaperones at the atomic level by measuring the attenuation of the NMR signal intensity and chemical-shift perturbations using two-dimensional spectroscopy. This process systematically discovered a specific pattern that determines the exact interaction site of α-synuclein with the assisting proteins:
Lead study author Sebastian Hiller, PhD, professor of structural biology at the University of Basel, described the interaction as not a fixed, rigid interaction, but a “dynamic and constantly changing encounter,” said Hiller. Researchers found that when chemical modifications of α-synuclein occur, such as those seen in PD, chaperone binding is impaired, which inhibits their ability to be a molecular bodyguard. These exposed α-synuclein proteins can then relocalize and accumulate on the membrane of the mitochondria, gradually destroying cells in the process.
As Lewy bodies typical for PD consist of membrane fragments and α-synuclein, Hiller stressed the role of chaperones as much more than an assisting protein. “Chaperones do far more than just assist in protein folding. They control cellular processes by flexibly interacting with a variety of proteins and accompanying them like a shadow,” said Hiller. As PD is one of the most common neurodegenerative disorders, further research into molecular interactions, as well as chaperones and the maintenance of their function, is warranted in developing innovative therapies.
Reference
Burmann BM, Gerez JA, Matečko-Burmann I, et al. Regulation of α-synuclein by chaperones in mammalian cells. [published online December 4, 2019]. Nature. doi: 10.1038/s41586-019-1808-9.
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
PD Worsens QOL, Increases Depression in Men More Than Women in the Southeast
February 17th 2023The southeastern areas of the country have worse health outcomes and health-related quality of life (HRQOL) compared with other parts of the United States, with high rates of diabetes, obesity, cancer, and cardiovascular disease.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen